

Pneumococcal Conjugate Vaccines

Vaccine Description	<ul style="list-style-type: none"> • Brand: VAXNEUVANCE™ (PCV15) • Brand: Prevnar 20™ (PCV20) • Inactivated protein-conjugated vaccines • Contain diphtheria protein and aluminum phosphate • See package inserts for more information and full lists of vaccine components
Dose & Route	<ul style="list-style-type: none"> • Dose: 0.5 mL • Route: IM
Indications	<ul style="list-style-type: none"> • Persons ≥ 65 years of age • Persons 19-64 years of age with no or unknown PCV receipt and certain risk factors: <ul style="list-style-type: none"> • Alcoholism or cigarette smoking • Cerebrospinal fluid (CSF) leak • Chronic heart disease (e.g., heart failure and cardiomyopathies) • Chronic liver disease (e.g., cirrhosis) • Chronic lung disease (e.g., COPD, emphysema, and asthma) • Cochlear implant • Diabetes mellitus • Immunocompromising conditions (e.g., chronic renal failure; congenital or acquired asplenia; congenital or acquired immunodeficiencies [e.g., HIV, B or T-lymphocyte deficiency, complement deficiencies, and phagocytic disorders, excluding chronic granulomatous disease]; generalized malignancy; Hodgkin disease; iatrogenic immunosuppression [e.g., treatment with immunosuppressive drugs, including long-term systemic corticosteroids and radiation therapy]; leukemia; lymphoma; multiple myeloma; nephrotic syndrome; sickle cell disease or other hemoglobinopathies; and solid organ transplant)

Pneumococcal Conjugate Vaccines

(Continued)

Administration Schedule	<ul style="list-style-type: none">• VAXNEUVANCE™ (PCV15)• One time dose, may be followed by a dose of PPSV23• Prevnar 20™ (PCV20)• One time dose; when PCV20 is used, no subsequent PPSV23 is recommended• See Pneumococcal Vaccine Schedule tables on the following pages for specific dosing and intervals.
Contraindications	<ul style="list-style-type: none">• Serious reaction (e.g., anaphylaxis) after a previous dose of pneumococcal vaccine, to any vaccine containing diphtheria toxoid, or to a vaccine component (including yeast)
Precautions	<ul style="list-style-type: none">• Moderate or severe acute illness with or without fever.
Special Considerations	<ul style="list-style-type: none">• Pregnancy: provider may consider giving if increased risk for infection or poor outcome from infection.• For individuals with anatomic or functional asplenia and/or HIV: PCV vaccines and Menactra (MenACYW-D) should not be given concomitantly. Administer Menactra ≥ 4 weeks after completion of all PCV doses.
VIS: http://www.cdc.gov/vaccines/hcp/vis/vis-statements/pcv.html MMWR: https://www.cdc.gov/mmwr/volumes/72/rr/rr7203a1.htm Standing Orders: www.health.mil/standingorders Additional education may be found at www.health.mil/pneumococcal	

Pneumococcal Polysaccharide Vaccine

Vaccine Description	<ul style="list-style-type: none"> • Brand: PNEUMOVAX 23® (PPSV23) • Inactivated bacterial polysaccharide vaccine • Contains phenol • See package insert for more information and a full list of vaccine components
Dose & Route	<ul style="list-style-type: none"> • Dose: 0.5 mL • Route: IM or SC
Indications	<ul style="list-style-type: none"> • Persons ≥ 65 years of age • Persons 19-64 years of age with certain risk factors (see Pneumococcal Conjugate Vaccines – Adult above) who previously received PCV13 or PCV15. • Not indicated for individuals who previously received PCV20.
Administration Schedule	<ul style="list-style-type: none"> • One or two doses after receipt of PCV13 or PCV15 • When PCV20 is used, no subsequent PPSV23 is recommended. • See Pneumococcal Vaccine Schedule tables on the following pages for specific dosing and intervals.
Contraindications	<ul style="list-style-type: none"> • Serious reaction (e.g., anaphylaxis) after a previous dose of pneumococcal vaccine or to a vaccine component.
Precautions	<ul style="list-style-type: none"> • Moderate or severe acute illness with or without fever. • Persons with severely compromised cardiovascular or pulmonary function in whom a systemic reaction would pose a significant risk.
Special Considerations	<ul style="list-style-type: none"> • Pregnancy: provider may consider giving if increased risk for infection or poor outcomes from infection.
<p>VIS: https://www.cdc.gov/vaccines/hcp/vis/vis-statements/ppv.html MMWR: https://www.cdc.gov/mmwr/volumes/72/rr/rr7203a1.htm Standing Orders: www.health.mil/standingorders Additional information: www.health.mil/pneumococcal</p>	

Pneumococcal Vaccine Schedule (Adult) Age ≥ 65 years		Do not give pneumococcal conjugate (PCV) and pneumococcal polysaccharide (PPSV) vaccine at the same visit.	
Vaccine received previously (any age)	Any or no underlying condition	No immunocompromising condition, CSF leak, or cochlear implant*	Immunocompromising condition, CSF leak, or cochlear implant*
	Option A: PCV20 available	Option B: PCV15 and PPSV23 available	Option B: PCV15 and PPSV23 available
None/unknown or PCV7 only	PCV20	PCV 15 PPSV 23	PCV 15 PPSV 23
PPSV23 only	≥ 1 year PCV20	≥ 1 year PCV 15 PPSV 23	≥ 8 wks PCV 15 PPSV 23
PCV13 only	≥ 1 year PCV20	≥ 1 year PPSV23	≥ 8wks PPSV23
Both PCV13 and PPSV23 (in any order) but no dose of PPSV23 at age ≥ 65 years	≥ 5 years since last PCV13 or PPSV23 PCV 20	≥ 1 year since PCV13 & ≥ 5 years since PPSV23 PPSV 23	≥ 8 wks since PCV13 & ≥ 5 years since PPSV23 PPSV 23
Both PCV13 and PPSV23 (in any order) and the PPSV23 was at age ≥ 65 years	Using shared clinical decision making: ≥ 5 years since last PCV13 or PPSV23 PCV20	Not Recommended	

Pneumococcal Vaccine Schedule (Adult) Age 19 – 64 years with risk factors		Do not give pneumococcal conjugate (PCV) and pneumococcal polysaccharide (PPSV) vaccine at the same visit.	
Vaccine received previously (any age)	Option A: PCV20 available	Option B: PCV15 and PPSV23 available	
Chronic medical condition*			
None/unknown or PCV7 only	PCV20	PCV 15	≥ 1 year → PPSV 23
PPSV23 only	≥ 1 year since PPSV23 → PCV20	≥ 1 year since PPSV23 →	PCV15
PCV13 only	≥ 1 year since PCV13 → PCV20	≥ 1 year since PCV13 →	PPSV23
PCV13 and PPSV23	Not recommended: review recommendations again at 65 years of age		
CSF leak or cochlear implant			
None/unknown or PCV7 only	PCV20	PCV 15	≥ 8 wks → PPSV 23
PPSV23 only	≥ 1 year since PPSV23 → PCV20	≥ 1 year since PPSV23 →	PCV15
PCV13 only	≥ 1 year since PCV13 → PCV20	≥ 8 wks since PCV13 →	PPSV23
PCV13 and 1 dose PPSV23	≥ 5 years since last dose → PCV20	Not recommended: review recommendations again at 65 years of age	
Immunocompromising condition*			
None/unknown or PCV7 only	PCV20	PCV 15	≥ 8 wks → PPSV 23
PPSV23 only	≥ 1 year since PPSV23 → PCV20	≥ 1 year since PPSV23 →	PCV15
PCV13 only	≥ 1 year since PCV13 → PCV20	≥ 8 wks since PCV13 →	PPSV23 → ≥ 5 years → PPSV23
PCV13 and 1 dose PPSV23 (in any order)	≥ 5 years since last dose → PCV20	≥ 8 wks since PCV13 → & ≥ 5 years since PPSV23 →	PPSV23
PCV13 and 2 doses PPSV23 (in any order)	≥ 5 years since last dose → PCV20	Not recommended: review recommendations again at 65 years of age	